A T2DM patient on metformin and sitagliptin is switched to a SGLT2 inhibitor (empagliflozin) due to cardiovascular comorbidity. The cardiorenal protective mechanism of empagliflozin beyond glucose-lowering operates through:
- A Reduced tubuloglomerular feedback via decreased tubular glucose sensing triggering afferent arteriolar vasodilation
- B Direct PPAR-gamma agonism in cardiac adipose tissue reducing epicardial fat inflammation
- C Inhibiting sodium-hydrogen exchanger NHE1 in cardiomyocytes reducing myocardial sodium overload
- D Osmotic diuresis and natriuresis reducing preload and afterload with decreased sympathetic activation and reduced intraglomerular pressure through tubuloglomerular feedback restoration ✓
Explanation
SGLT2 inhibitors block glucose and sodium co-transport in the proximal tubule, causing glucosuria and natriuresis. Increased distal tubular NaCl delivery restores tubuloglomerular feedback-mediated afferent arteriolar constriction, reducing intraglomerular pressure and hyperfiltration (a key mechanism of diabetic nephropathy). Simultaneously, osmotic diuresis reduces plasma volume, preload, and afterload with paradoxically less neurohumoral activation compared to loop diuretics. Additionally, ketone body utilization by the heart as efficient fuel (the 'thrifty substrate' hypothesis) and NHE1 inhibition in cardiomyocytes have been proposed as supplementary cardiac mechanisms, but the tubuloglomerular feedback and hemodynamic effects are best established.
Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.